BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a sell rating to a hold rating in a research report report published on Tuesday morning.
Other equities research analysts have also issued reports about the company. Piper Jaffray Companies lifted their price target on Deciphera Pharmaceuticals to $50.00 and gave the company an overweight rating in a report on Tuesday, June 12th. Guggenheim started coverage on Deciphera Pharmaceuticals in a report on Monday, September 17th. They set a buy rating for the company. Cantor Fitzgerald started coverage on Deciphera Pharmaceuticals in a report on Thursday, September 6th. They set a buy rating and a $53.00 price target for the company. Canaccord Genuity started coverage on Deciphera Pharmaceuticals in a report on Tuesday, August 7th. They set a buy rating and a $55.00 price target for the company. Finally, Zacks Investment Research lowered Deciphera Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, August 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. Deciphera Pharmaceuticals presently has an average rating of Buy and a consensus target price of $48.09.
NASDAQ:DCPH opened at $38.26 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.44 and a current ratio of 18.44. Deciphera Pharmaceuticals has a fifty-two week low of $15.15 and a fifty-two week high of $45.61. The stock has a market cap of $1.50 billion and a price-to-earnings ratio of -12.80.
Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in Deciphera Pharmaceuticals by 316.1% in the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after purchasing an additional 1,982 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Deciphera Pharmaceuticals in the 1st quarter worth approximately $152,000. New York State Common Retirement Fund lifted its holdings in Deciphera Pharmaceuticals by 37.5% in the 1st quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock worth $198,000 after purchasing an additional 2,700 shares during the last quarter. Trexquant Investment LP acquired a new stake in Deciphera Pharmaceuticals in the 2nd quarter worth approximately $203,000. Finally, Rhumbline Advisers acquired a new stake in Deciphera Pharmaceuticals in the 2nd quarter worth approximately $301,000. Institutional investors and hedge funds own 53.53% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Recommended Story: Growth Stocks
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.